The gene expression level of IFN-?R1 and IFN-?R2 in a murine model treated with Toxoplasma gondii and its products
Gastroenterology and Hepatology from Bed to Bench,
Vol. 9 No. 2 (2016),
17 March 2016
,
Page 124-131
https://doi.org/10.22037/ghfbb.v9i2.882
Abstract
Aim: To evaluate the effect of active T. gondii tachyzoites and its products on the gene expression level of IFN-yR1 and IFN-yR2 in a murine model.
Background: Many studies have shown that the parasite Toxoplasma gondii utilizes different mechanisms to inhibit the function of IFN-?, but the parasite effect on the function of IFN-yR1 and IFN-yR2 is still unclear.
Patients and methods: Toxoplasma lysate product (TLP), excretory/secretory products (ESPs) obtained from cell free and cell culture media as well as active tachyzoites were injected separately to their respective group each consisted of 10 BALB/c mice. One control group of 10 mice received phosphate buffered saline (PBS). All of the mice were euthanized three days after the last injection and then their peritoneal leukocytes were harvested separately. The total RNA was extracted from the samples, converted to cDNA, and the gene expression level of IFN-yR1 and IFN-yR2 was assessed in all of the treated groups relative to the control one.
Results: There was no significant difference between each of the treated groups relative to the control group concerning the gene expression level of IFN-yR2 (P> 0.05). Furthermore, the gene expression level of IFN-yR1 in two groups of TLP (P= 0.04) and ESP obtained from cell free medium (P= 0.008) showed a significant difference relative to the control group.
Conclusion: Findings of this study revealed a new aspect of host-T. gondii interaction in that this parasite is able to downregulate IFN-yR1 to reduce the IFN-y effects on the infected cell.
- Toxoplasma gondii
- gene expression
- IFN-?R1
- IFN-?R2
How to Cite
References
Dubey, JP. The history and life cycle of Toxoplasma gondii. In: Louis M, Kim W, Kim K, editors, Toxoplasma gondii. 1st edition, London: Elsevier, 2007;p:1-12.
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis 2012;44:805-814.
Blader IJ, Saeij JP. Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS 2009;117:458-476.
Walker DM, Oghumu S, Gupta G, McGwire BS, Drew ME, Satoskar AR. Mechanisms of cellular invasion by intracellular parasites. Cell Mol Life Sci 2014;71:1245-1263.
Sweeney KR, Morrissette NS, LaChapelle S, Blader IJ. Host cell invasion by Toxoplasma gondii is temporally regulated by the host microtubule cytoskeleton. Eukaryot Cell 2010;9:1680-1689.
Melo MB, Jensen KD, Saeij JP. Toxoplasma gondii effectors are master regulators of the inflammatory response. Trends Parasitol 2011;27:487-95.
Xia D, Sanderson SJ, Jones AR, Prieto JH, Yates JR, Bromley E, et al. The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation. Genome Biol 2008;9:R116.
Crater AK, Manni E, Ananvoranich S. Utilization of inherent miRNAs in functional analyses of Toxoplasma gondii genes. J Microbiol Methods 2015;108:92-102.
Franco M, Shastri AJ, Boothroyd JC. Infection by Toxoplasma gondii specifically induces host c-Myc and the genes this pivotal transcription factor regulates. Eukaryot Cell 2014;13:483-493.
Lin DB, Su KE, Yu JC. Studies on cryopreservation of Toxoplasma gondii and its antigenicity in mice. Am J Trop Med Hyg 1995;53:392-396.
Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci 2009;18:24-36.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
Tait ED, Jordan KA, Dupont CD, Harris TH, Gregg B, Wilson EH, et al. Virulence of Toxoplasma gondii is associated with distinct dendritic cell responses and reduced numbers of activated CD8+ T cells. J Immunol 2010;185:1502-1512.
Robben PM, Mordue DG, Truscott SM, Takeda K, Akira S, Sibley LD. Production of IL-12 by macrophages infected with Toxoplasma gondii depends on the parasite genotype. J Immunol 2004;172:3686-3694.
Skariah S, McIntyre MK, Mordue DG. Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion. Parasitol Res 2010;107:253-60.
Halonen SK, Taylor GA, Weiss LM. Gamma interferon-induced inhibition of Toxoplasma gondii in astrocytes is mediated by IGTP. Infect Immun 2001;69:5573-5576.
Butcher BA, Fox BA, Rommereim LM, Kim SG, Maurer KJ, Yarovinsky F, et al. Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control. PLoS Pathog 2011;7:e1002236.
Butcher BA, Kim L, Panopoulos AD, Watowich SS, Murray PJ, Denkers EY. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages. J Immunol 2005;174:3148-3152.
Cai Y, Chen H, Mo X, Tang Y, Xu X, Zhang A, et al. Toxoplasma gondii inhibits apoptosis via a novel STAT3-miR-17-92-Bim pathway in macrophages. Cell Signal 2014;26:1204-1212.
Saraiva M, O'Garra, A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-181.
Sherman MA. The role of STAT6 in mast cell IL-4 production. Immunol Rev 2001;179:48-56.
Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle, GB. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J Immunol 2005;174:1027-1036.
Du J, An R, Chen L, Shen Y, Chen Y, Cheng L, et al. Toxoplasma gondii virulence factor ROP18 inhibits the host NF-κB pathway by promoting p65 degradation. J Biol Chem 2014;289:12578-12592.
Stutz A, Kessler H, Kaschel ME, Meissner M, Dalpke AH. Cell invasion and strain dependent induction of suppressor of cytokine signaling-1 by Toxoplasma gondii. Immunobiology 2012;217:28-36.
Kim SK, Fouts AE, Boothroyd JC. Toxoplasma gondii dysregulates IFN-gamma-inducible gene expression in human fibroblasts: insights from a genome-wide transcriptional profiling. J Immunol 2007;178:5154-5165.
Gavrilescu LC, Denkers EY. IFN-gamma overproduction and high level apoptosis are associated with high but not low virulence Toxoplasma gondii infection. J Immunol 2001;167:902-909.
Mordue DG, Monroy F, La Regina M, Dinarello CA, Sibley LD. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol 2001;167:4574-4584.
Deckert-Schlüter M, Rang A, Weiner D, Huang S, Wiestler OD, Hof H, et al. Interferon-gamma receptor-deficiency renders mice highly susceptible to toxoplasmosis by decreased macrophage activation. Lab Invest 1996;75:827-841.
Zhao Y, Wilson D, Matthews S, Yap GS. Rapid elimination of Toxoplasma gondii by gamma interferon-primed mouse macrophages is independent of CD40 signaling. Infect Immun 2007;75:4799-4803.
- Abstract Viewed: 218 times
- PDF Downloaded: 111 times